Prof. Kausik Ray
One of the most pre-eminent preventative cardiologists in the world, with over 55,000 citations for my research and over 280 publications in top-quality peer-reviewed journals, I am the Professor of Public Health and Honorary Cardiologist at Imperial College London.
There is a new class of cholesterol-lowering medicine which will soon be available and could help people who need their cholesterol lowering further, those who cannot tolerate statins, or those who can't afford expensive injections. I and my colleagues recently published two papers in the New England Journal of Medicine showing the largest evidence of safety and effectiveness of this new treatment, called Bempedoic Acid. Read the media coverage here:
A study was badly reported in the media recently, with deliberately shocking headlines claiming "half of those on statins won't have 'healthy' cholesterol after two years' of taking the pills". Fortunately I had the opportunity to correct journalists' interpretation of the (purely observational) study and respond to headlines which must have worried a vast number of statin users. In short, you have to be on the correct dose and take the medication every day for it to be effective. If you are on a dose which is too low and you don't take the pills every day, then you obviously will not achieve the desired outcome. Coverage:
The Lancet recently published a study about the 'Polypill', a cost-effective single pill combining four drugs which helps to reduce blood pressure and cholesterol and shows some cardiovascular benefits, such as reducing the risk of heart attacks, strokes and sudden death. Although the trial and implications are more relevant for low- and middle-income countries, in the UK as many as a third of people with high blood pressure are undiagnosed and, amongst those who are diagnosed, many don't manage their condition properly. Coverage:
The Daily Mail has recently investigated three prominent UK Statin Deniers and their devastating effect upon the health of members of the public, thousands of whom continue to have a far higher risk of a heart attack or stroke because these unqualified persons have cast so much doubt upon statins' efficacy in their ongoing anti-statin propaganda. These three have been condemned by the Health Secretary (who called their claims 'pernicious lies') and 30 Editors-In-Chief of major heart-health journals. Read the articles here:
My recent paper looking at statins dose and adherence, and cardiovascular deaths, as published in JAMA Network Open, was universally acclaimed within the scientific community and widely reported in the British press; even garnering a front page on both the iPaper and Express. Full coverage:
In the News
I presented the 18 month safety data of the ORION-4 trial, which is testing the cholesterol-lowering drug, inclisiran, for safety. The drug shows remarkable results - with an initial injection, one at 3 months and thereafter one jab every 6 months - patients had an average reduction of cholesterol of 54% with, most importantly, no adverse safety signals. This is a novel and very exciting treatment which should make a huge difference in the lives of everyone with high cholesterol, particularly those who cannot tolerate statins and those who struggle to remember to take their medications on a daily basis. Full media coverage:
I was recently asked to provide an expert opinion on the statins debate by Virgin Media television; in this article I set out the minor side effects which occur, how common they are (evidence backed up by large randomised controlled trials), and how effective statins are at preventing future cardiovascular events, particularly in those who have already had a heart attack or stroke. Hopefully this will help people make the best decision for their own health:
My Latest Research
At the recent ESC in Paris, I discuss the results of the Phase 3 ORION-11 trial: the impact of Inclisiran on LDL-C over 18 months in patients with ASCVD or equivalent. Watch it here:
I gave a lecture at the recent EAS on risk prediction, particularly on the interaction between relative and absolute risk - what they are and what factors influence them. View it here:
Please do watch my key takeaways from the recent EASD conference: cardiac risk reduction should be a priority for diabetic patients and the importance of cardiometabolic disease management:
I am pleased to announce my latest paper, "Pharmacological Lipid Modification Therapies for the Prevention of Ischaemic Heart Disease-Current and Future Options"published in the Lancet is available to read now:
Please do read a recent paper authored by myself and my visiting international fellow, published in the Journal Frontiers of Medicine, explaining new therapies and methods to lower bad cholesterol:
I am proud to announce my paper explaining the common mechanism through which triglycerides and cholesterol increase heart disease has just been published in JAMA. Read it here:
I spoke about Bempedoic Acid at this year's ESC; watch my interview with Radcliffe Cardiology here:
At this year's ESC I talked about Statins, Diabetes and Glucose Metabolism: Challenging Cases and Considerations and also about Statins and the Elderly. Watch both videos here:
At the recent American Diabetes Association Congress I discussed Statins, Diabetes and Glucose Metabolism - watch it here:
I was delighted to be included in the ESC's "Best of 2017" research roundup, for our research on prediction of CV events in FH patients
I discuss micro- and macrovascular disease in type 2 diabetes, the implications and risk modification with new glucose-lowering agents
I was interviewed at the 2017 American Heart Association Congress on High vs Moderate dosing for the secondary prevention of coronary artery disease:
Listen to a recent CIRCULATION Podcast outlining analyses from the WOSCOPS trial and the importance of LDL-C lowering for the primary prevention of CV disease amongst men.
I was interviewed about the efficacy and safety of Alirocumab in patients with diabetes at the recent EASD Congress; watch it here:
Here I discuss the key take home message of the WOSCOPS study for clinicians:
I also recorded a program at the ESC on the results of the ORION data for Medscape, discussing siRNA (emerging gene silencing therapies) and PCSK9s:
At the recent European Society of Cardiology Congress in Paris I recorded the following educational presentation, explaining how we select statin doses to address intolerance:
I recently presented results for THEMIS at the ESC, a trial which has helped define the role of anti-platelet therapy in those with CAD and Type 2 Diabetes. Watch here (password: AZesc2019):
Here I discuss the key issues and challenges impacting clinical management with novel cholesterol-lowering therapeutics:
New insights on lipid management have emerged since 2016; here I discuss with Francois Mach ways in which guidelines should be changed:
I am delighted to announce that my paper on global insulin use has just been published in the Journal of Diabetes, Obesity and Metabolism. Read it here:
Read about my global FH initiative in this EAS publication. 1 in 250 people globally have genetically determined elevations in cholesterol - get screened now.
During the recent ESC I spoke with Congress Report about the CLEAR Harmony, a trial testing a new therapeutic compound for patients with high CV risk. Watch my summary here:
I recently had the honour of saying a few words at my good friend Prof Kees Hovingh's inaugural speech; watch me speak about Today's Trials and Tomorrow's Treatments:
Watch my discussion on Familial Hypercholesterolaemia for Congress Report at the 2018 EAS Congress, Lisbon.
Watch my presentation at the recent American College of Cardiology congress in which I evaluated the evidence for lower LDL-C goals
Read my research from the WOSCOPS study showing that a small daily dose of statins in primary prevention patients reduces deaths from heart disease in participants by over 25%.
Watch me discuss the analysis of the WOSCOPS study with Lead Author, Dr Antonio Vallejo-Vaz
Watch me talk about the primary results of the Exenatide Study of Cardiovascular Event Lowering at the recent European Association for the Study of Diabetes (EASD) Congress